May 2008
Volume 49, Issue 13
ARVO Annual Meeting Abstract  |   May 2008
Intravitreal Pegaptanib Sodium for Choroidal Neovascularization Secondary to Age-Related Macular Degeneration- A Pan-European Experience
Author Affiliations & Notes
  • S. Sivaprasad
    Ophthalmology, Moorfields Eye Hospital, Essex, United Kingdom
    Clayton Eye Hospital, Wakefield, United Kingdom
  • A. Saeed
    Ophthalmology, Waterford regional Hospital, Waterford, Ireland
  • S. Beatty
    Ophthalmology, Waterford Regional Hospital, Waterford, Ireland
  • J. L. Olea
    Ophthalmology, Hospital Son Dureta, Islas Baleares, Spain
  • S. Grisanti
    University Eye Hospital, Dept of Ophthalmology, Eberhard-Karls University of Tuebingen, Germany, Germany
  • C. Rosina
    Ophthalmology, Luigi Sacco Department of Clinical Science, University of Milano, Italy
  • G. Staurenghi
    Ophthalmology, Department of Clinical Science, Luigi Sacco, University of Milano, Italy
  • P. Hykin
    Ophthalmology, Moorfields Eye Hospital, London, United Kingdom
  • Footnotes
    Commercial Relationships  S. Sivaprasad, Research and travel grants, R; A. Saeed, None; S. Beatty, Research and travel grants, R; J.L. Olea, Research and travel grants, R; S. Grisanti, Research and travel grants, R; C. Rosina, None; G. Staurenghi, Research and travel grants, R; P. Hykin, Research and travel grants, R.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 335. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      S. Sivaprasad, A. Saeed, S. Beatty, J. L. Olea, S. Grisanti, C. Rosina, G. Staurenghi, P. Hykin; Intravitreal Pegaptanib Sodium for Choroidal Neovascularization Secondary to Age-Related Macular Degeneration- A Pan-European Experience. Invest. Ophthalmol. Vis. Sci. 2008;49(13):335. doi:

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : The phase III studies of pegaptanib sodium [VEGF Inhibition Study in Ocular Neovascularization trials (VISION)] showed that 6 weekly pegaptanib sodium when given as intravitreous injections to patients with subfoveal choroidal neovascularization secondary to ARMD stabilised vision (loss of less than 15 letters ETDRS) in 70% . Gain of vision (gain of ≥15 letters ETDRS) was noted in 6%. This aim of this audit is to compare the visual outcome obtained in real-life experience with pegaptanib sodium with that of the VISION study.

Methods: : A combined cohort of 164 patients from 5 different European countries was included. Consecutive patients with any angiographic subtype of subfoveal choroidal neovascularization secondary to AMD and best-corrected visual acuities (BCVA) in the study eye of 20/40 to 20/320 that received 0.3mg pegaptanib sodium as the first-line treatment were included. After 3 doses of six-weekly pegaptanib sodium, a PRN dosing schedule was followed. The final follow-up is 24 weeks.

Results: : The mean baseline visual acuity was 43.3 ETDRS letters and the mean baseline lesion size was 3664 um. 90.2% stabilised vision and 14.6% gained more than 15 letters. The average change in visual acuity for all lesions was a loss of 1.7 letters. Lesion subtypes and baseline lesion size did not influence the final visual outcome.

Conclusions: : The visual acuity outcome with Pegaptanib sodium was better than the VISION study despite a PRN dosing schedule.

Keywords: age-related macular degeneration • visual acuity • retina 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.